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Highlights: 
 Film-coated microparticles were developed for colon-specific drug delivery 
 Starch-coated films showed improved acidic and enzymatic resistance in the GI tract 
 Native and retrograded starches were used as binders to reinforce the resistance 
 Suitable molecular mass and high crystallinity of starch are important factors 
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ABSTRACT： 
The aim of this study was to prepare and characterize a novel type of starch-coated 
microparticles (MPs) allowing site-specific delivery of bioactives to the colon. An oral 
colon-specific controlled-release system was developed in the form of MPs coated with a resistant 
starch (RS2/RS3) film (RS@MPs) through an aqueous suspension coating process. The RS2 was 
chosen from a high-amylose cornstarch with 88.5% digestion resistibility. The RS3 was prepared by 
a high-temperature/pressure (HTP) treatment, with the following of enzymatic debranching, and 
retrogradation, resulting in a dramatic increase in enzymatic resistance (RS3 content: 76.6%). 
RS@MPs showed 40.7% of 5-aminosalicylic acid release within 8h. The in vivo study of 
fluorescein-loaded RS@MPs indicated the high acidic and enzymatic resistibility of RS@MPs and a 
restrained release in the upper GIT. Therefore, RS@MPs has revealed to be a high potential system 
for accurately targeting bioactive compound delivery to the colon. 
 
Keywords: 
Resistant starch; aqueous suspension film coating; controlled release; oral colon-specific delivery. 
 
Chemical compounds studied in this article 
Starch (PubChem CID: 24836924); Water (PubChem CID: 962); Ethanol (PubChem CID: 702); 
Sodium hydroxide (PubChem CID: 14798); Acetic acid (PubChem CID: 176); Iodine (PubChem 
CID: 807); Potassium iodine (PubChem CID: 4875); D-Glucose (PubChem CID: 5793); 
Hydrochloric acid (PubChem CID: 313); Phenol (PubChem CID: 996); Sulfuric acid (PubChem CID: 
1118); Potassium dihydrogen phosphate (PubChem CID: 516951); Dipotassium hydrogen phosphate 
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(PubChem CID: 24450); Citric acid (PubChem CID: 311); Dimethyl sulfoxide (DMSO) (PubChem 
CID: 679); Lithium bromide (PubChem CID: 82050); 5-aminosalicylic acid (5-ASA) (PubChem 
CID: 4075); Triethyl citrate (PubChem CID: 6506); Fluorescein isothiocyanate (FITC) (PubChem 
CID: 18730); Isoflurane (PubChem CID: 3763); Potassium chloride (PubChem CID: 4873); Sodium 
chloride (PubChem CID: 5234); 4’,6-diamidino-2-phenylindole (DAPI) (PubChem CID: 2954). 
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Nomenclature 
5-ASA 5-aminosalicylic acid 
DAPI 4’,6-diamidino-2-phenylindole 
DDSs drug delivery systems 
DMSO dimethyl sulfoxide 
FITC fluorescein isothiocyanate 
G50 Gelose 50 
G80 Gelose 80 
GIT gastrointestinal tract 
GPC gel permeation chromatography 
HACS high-amylose cornstarch 
HPMC hydroxypropyl methylcellulose 
HTP high-temperature/pressure 
IVIS in vivo imaging system 
MALS multi-angle light scattering 
Mn number-average molecular weight 
MPs microparticles 
Mw weight-average molecular weight 
NCS normal cornstarch 
OCT optimum cutting temperature 
PBS phosphate buffered saline 
PVP povidone 
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RC relative crystallinity 
RDS rapidly digestible starch 
RS resistant starch 
RS@MPs RS2/RS3 film-coated MPs 
SCFA short-chain fatty acids 
SDS slowly-digestible starch 
SEM scanning electron microscope 
SGF simulated gastric fluid 
SIF simulated intestinal fluid 
WCS waxy cornstarch 
XRD X-ray diffraction 
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1. Introduction 
Emphasis has been placed on controlling the rate and/or site of bioactive compounds released 
from oral formulations for improving the therapeutic potentials (Sastry, Nyshadham & Fix, 2000). 
The colon is one area that would benefit from the development and use of such controlled release 
technologies. Colon-specific drug delivery systems (DDSs) have attracted many researchers due to 
distinct advantages such as near neutral pH, long transit time and reduced enzymatic activity (Haupt 
& Rubinstein, 2002). Delivery of active compounds to the colon can highly benefit for various 
applications, including the reduced administered dosage and side effect of anti-inflammatory drugs 
for local treatments, and the avoidance of unwanted digestion and the improved bioavailability of 
protein drugs for systemic absorption (Vinaykumar, Sivakumar, Tamizhmani, Rajan & Chandran, 
2011).  
An ideal colon-specific DDS should effectively suppress the release of active compounds in the 
stomach and small intestine. However, there could be some technical challenges, which are 
associated with the pH variations along the gastrointestinal tract (GIT), the digestion enzymes, and 
the long transit time (Hamman, Enslin & Kotzé, 2005). To overcome these obstacles, recent 
developments in polymeric materials offer opportunities to facilitate the advance of colon delivery 
carriers, including the use of bacteria-degradable, pH-sensitive, pressure-sensitive, and 
time-dependent coating polymers (Lin, Chen & Luo, 2007; Maroni, Zema, Del Curto, Foppoli & 
Gazzaniga, 2012; Said, 2005). Among materials susceptible to colonic biodegradation, the interest in 
polysaccharides has grown strongly in recent years because of their nontoxicity, safety, and good 
biocompatibility (Sinha & Kumria, 2001). In particular, starch, as the second abundant 
polysaccharide, has received considerable attention due to its low cost, diversity of source, and high 
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availability (Remon, Voorspoels, Radeloff & Beck, 1996). The starch that is not hydrolyzed in the 
small intestine but can be degraded by colon microorganisms, is considered as resistant starch (RS) 
(Thompson, 2000), which plays an important role in digestive physiology (Fuentes-Zaragoza, 
Riquelme-Navarrete, Sánchez-Zapata & Pérez-Álvarez, 2010). RS is normally classified into five 
main types, namely RS1, RS2, RS3, RS4, and RS5 (Fuentes‐ Zaragoza et al., 2011). These RSs can 
offer additional advantages of starch as colon-specific carrier materials, as the fermentation of RSs 
by anaerobic microflora in the colon can produce short-chain fatty acids (SCFA) (Rubinstein, 1990). 
These SCFA may play an important role in maintaining health by reducing the risk of diseases, such 
as inflammatory diseases, Type 2 diabetes, obesity, and heart disease (Ríos-Covián, Ruas-Madiedo, 
Margolles, Gueimonde, de los Reyes-Gavilán & Salazar, 2016).  
For the purposes of controlled release and colon targeting, a well-accepted concept is to realize 
dosage forms to encapsulate active compounds with polymeric film coatings. Especially, much 
attention has been paid to the development of aqueous film coatings, instead of organic solvent, for 
safety, economic, and environmental reasons (Iyer, Hong, Das & Ghebre-Sellassie, 1990). Starch has 
been extensively evaluated for its film-forming ability as drug delivery coatings (Palviainen, 
Heinämäki, Myllärinen, Lahtinen, Yliruusi & Forssell, 2001). However, due to the hydrophilicity of 
starch and with the aim to avoid unwanted release of bioactives in the upper GIT, starches that are 
used as coating films need to be modified to possess particular features such as insolubility and 
impermeability (Cummings et al., 1996; Siccardi, Turner & Mrsny, 2005), resulting from the 
resistance to the acidic gastric pH or intestinal enzymes in the upper GIT (Chourasia & Jain, 2004). 
Up to now, most studies of starch-based films for colon-specific delivery have focused on blending 
commercially available polymers with starch derivatives to effectively control the physicochemical 
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properties of the blended coating films based on, e.g., peas starch/ethylcellulose (Karrout et al., 
2011), high-amylose starch/Surelease® (Freire, Podczeck, Veiga & Sousa, 2009), and 
amylose/Ethocel® (Milojevic et al., 1996). Yet, motivated by the low cost and nontoxicity of starch, 
few studies have concerned the preparation of starch-only coating films for effective colon-specific 
delivery based on, for example, chemically modified resistant starch acetate (RS4) (Chen, Li, Li & 
Guo, 2007; Chen, Li, Pang, Li, Zhang & Yu, 2007; Chen, Pu, Li & Yu, 2011; Li, Liu, Chen & Yu, 
2011; Pu, Chen, Li, Xie, Yu & Li, 2011). Moreover, retrograded (recrystallized) starch (RS3) was 
also reported as a film coating material with a high potential for oral colon-specific delivery (Situ, 
Chen, Wang & Li, 2014). From this point, a colon-specific starch coating can be achieved merely by 
physically modified starch (retrograded RS3). Meanwhile, native starch granules can be a good 
source of RS2, which show high enzymatic resistance and can be hydrolyzed slowly by α-amylases 
(Chen, Liang, Li, Chen & Xie, 2016). The addition of particles to the coating may enhance its 
mechanical strength (Hari & Nair, 2016), which can help to counter intensive gastric digestion to 
avoid unwanted early release. Regarding this, if microparticles (MPs) loaded with bioactive 
compounds are coated with RS2/RS3 by an aqueous suspension film coating process, where the 
gelled starch molecules can aggregate with native starch particles that are suspended in the starch 
paste upon dehydration and drying, a colon-specific controlled-release system with high performance 
may be achieved. In this aqueous suspension system, native starch particles can maintain the high 
solid content while decreasing the viscosity of the suspension, thus reducing energy consumption 
(Borgquist, Zackrisson, Nilsson & Axelsson, 2002). In addition, due to the large size range of native 
RS2 particles, RS3 paste can also act as a binder to avoid the sediment of RS2 particles during the 
film coating process, and the reinforcement by RS2 granules has the high potential to allow the 
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formation of firm and compact films.  
The present investigation attempts to develop a colon-specific controlled-release system in the 
form of RS2/RS3 film-coated MPs (RS@MPs) by an aqueous suspension film coating process. The 
approach consisted of two key parts. The first part is the preparation of RS2/RS3 film, which could 
be achieved simultaneously by the aqueous film coating technique using suspensions consisting of 
raw starch particles (RS2) and RS3 pastes. RS3 pastes can be prepared by a 
high-temperature/pressure (HTP) treatment, followed by enzymatic debranching, and retrogradation. 
An attempt was also made to estimate the resistance of RS2 and RS3 to the acidic gastric pH or 
intestinal enzymes in the upper GIT by studying their characteristics and the digestion resistibility. 
The second part is about release tests to verify the potential of colon-specific controlled release. 
5-aminosalicylic acid (5-ASA) was chosen as an active compound to evaluate the release behavior of 
RS@MPs in in vitro experiments (i.e., under the conditions of simulated human GIT). Besides, to 
understand the biocompatibility, the in vivo effectiveness of RS@MPs was also evaluated by an in 
vivo imaging system (IVIS) and tissue histospectroscopy in mice. 
 
2. Materials and methods 
2.1. Materials 
Six commercially available cornstarches with different amylose/amylopectin ratios were used in 
this experimental work: (1) Gelose 80 (G80), supplied by Penford Australia Ltd. (Jannali, NSW, 
Australia); (2) Gelose 50 (G50), supplied by Penford Australia Ltd. (Jannali, NSW, Australia); (3) 
High-amylose cornstarch (HACS), supplied by Heilongjiang Huaneng Specialized Cornstarch Co., 
Ltd. (Heilongjiang, China); (4) Hylon V, supplied by National Starch and Chemical Co., Ltd. 
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(Bridgewater, NJ, USA); (5) Normal cornstarch (NCS), supplied by Inner Mongolia Yu Wang 
Biological Science Technology Co., Ltd. (Inner Mongolia, China); and (6) Waxy cornstarch (WCS), 
supplied by Qinhuangdao Lihua Starch Co., Ltd. (Hebei, China). 
Potato amylose was purchased from the Heilongjiang Academy of Agricultural Sciences (Harbin, 
China); Pepsin and pancreatin from Sigma-Aldrich Co., LLC (Santa Clara, CA, USA); D-Glucose 
from Sigma Chemical Co. (St. Louis, MO, USA); Porcine pancreatic α-amylase and 
amyloglucosidase from Sigma-Aldrich (St. Louis, MO, USA); Glucose-oxidase peroxidase assay kit 
from Megazyme International Ireland Ltd. (Wicklow, Ireland); Pullulanase from Yulibao Biology and 
Technology Co., Ltd. (Guangzhou, China); 5-ASA from Yuancheng Technology Development Co., 
Ltd. (Wuhan, China); Microcrystalline cellulose from Anhui Shanhe Medicinal Accessary Material 
Co., Ltd. (Huainan, China); Medicinal starch from Defeng Starch Sugar Co., Ltd. (Shunde District, 
Foshan, China); Povidone (PVP) k 30 and hydroxypropyl methylcellulose (HPMC) from Guangzhou 
Feibo Botechnological Co., Ltd. (Guangzhou, China); Fluorescein isothiocyanate (FITC) from 
Biotium Inc. (Fremont, California, USA); Optimum cutting temperature (OCT) compound 
(McCormick Cryo-STAT) from Changzhou Philas Instrument Co., Ltd. (Jiangshu, China); and 
4’,6-diamidino-2-phenylindole (DAPI) from Seajet Scientific Inc. (Beijing, China). 
 
2.2. Characterization of native starches 
2.2.1. Amylose content analysis 
The amylose contents of native starches (G80, HACS, Hylon V, G50, NCS, and WCS) were 
determined using a modified method of ISO 6647-2:2007 of the International Standardization 
Organization (ISO, 2007). Specifically, 0.1 g (dry basis) of the starch was weighed and dissolved in 1 
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mL of ethanol and 9 mL of sodium hydroxide solution (1 mol/L), which was then heated in boiling 
water for 10 min. After cooling off, this solution was diluted to 100 mL in a volumetric flask with 
deionized water. An aliquot (2.50 mL) of this solution was then diluted with 25.00 mL of water, 0.50 
mL of acetic acid solution (1 mol/L), 0.50 mL of I2/KI solution (0.0025 mol/L I2, and 0.0065 mol/L 
KI). The absorbance of this solution was read at 620 nm using an Evolution UV/vis 
spectrophotometer (Thermo Scientific, Waltham, USA). The amylose from potato (amylose content: 
97.0%) was used for the calibration curve (R2 = 0.9962). 
 
2.2.2. Digestion resistibility in the upper GIT 
The in vitro digestibility of six native starches (G80, HACS, Hylon V, G50, NCS, and WCS) was 
determined following the reported method (Thompson, Button & Jenkins, 1987) with modification. 
Duplicate 1 g (dry basis) of six native starches were weighed, suspended in 20 mL of simulated 
gastric fluid (SGF, pH 1.2) (Pu, Chen, Li, Xie, Yu & Li, 2011), and immediately placed in a dialysis 
bag (Spectra/Pro CE 131276T, molecular weight cutoff 8×103–10×103 g/mol), dialyzing against 500 
mL of SGF in a beaker at 37 °C for 2 h. During this time, the loaded dialysis bag was shaken every 
15 min to avoid starch sedimentation. After 2 h, a duplicate dialyzed starch sample was centrifuged, 
dried, ground and passed through a sieve (0.15 mm mesh size) for further use. These samples 
obtained from different starches were named as G80-SGF, HACS -SGF, Hylon V-SGF, G50-SGF, 
NCS-SGF, and WCS-SGF, respectively. While 1 mL of the dialysate samples were taken and 
analyzed for sugar release by the phenol-sulfuric acid method (Masuko, Minami, Iwasaki, Majima, 
Nishimura & Lee, 2005). Another duplicate sample was centrifuged, suspended in 20 mL of SIF. 
Then, the same procedure of the previous dialysis experiment was followed, except that SGF was 
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replaced by the simulated intestinal fluid (SIF, pancreatin, pH 6.8) (Pu, Chen, Li, Xie, Yu & Li, 2011) 
and the dialysis time was extended to 6 h. After that, these starch samples were mixed with ethanol to 
quench the enzyme activity, and then the dispersion was centrifuged at 3,000 g three times for 20 
min. The sediments, named G80-SIF, HACS-SIF, Hylon V-SIF, G50-SIF, NCS-SIF, and WCS-SIF, 
respectively, were centrifuged, dried, ground for further use. The dialysate samples were also used 
for sugar release analysis. D-Glucose was used for the calibration curve in SGF (R2 = 0.9991) and 
SIF (R2 = 0.9995). 
Granule morphology of six native starches and its hydrolyzed starch residues after 2 h of SGF 
and 6 h of SIF dialysis was studied using an EVO18 scanning electron microscope (SEM) (ZEISS, 
Germany) operated at a high voltage of 10.0 kV. Before SEM examination, the samples were coated 
with a gold thin film. 
 
2.3. Preparation of RS3 samples 
The modification involved the HTP treatment and the subsequent debranching of starch chains, 
according to our previously reported method (Situ, Chen, Wang & Li, 2014; Zhang, Chen, Zhao & Li, 
2013). Considering the greater recrystallization tendency of amylose in gelled starch pastes (Whistler 
& BeMiller, 1997) and the requirement of the debranching treatment of amylopectin by pullulanase, 
Hylon V, with the amylose content of about 51%, was chosen.  
50 g (dry basis) of Hylon V was dispersed in 200 mL water and cooked in a sealed reactor (Parr 
4545, Parr Instrument Co., USA) at 110 °C under a pressure of 12.4 MPa with stirring at 200 rpm for 
30 min. Then, the dispersion was cooled to 60 °C, and its pH value was adjusted to 5.0 using 10% 
(w/v) citric acid. Subsequently, different amounts of pullulanase (0, 50, 75, 100 and 200 ASPU/g dry 
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starch) were added for debranching the starch molecules at 60 °C under atmospheric pressure with 
stirring at 20 rpm for 2 h. The debranched starch was cooked at 100 °C for 10 min to stop the 
enzymatic hydrolysis, diluted to different concentrations of Hylon V paste (5%, 8%, 10%, 15%, and 
20%, w/w), and then stored at 4 °C for 36 h (during which retrogradation occurred) for further use.  
 
2.4. Characteristics of RS3 samples 
2.4.1. In vitro digestibility of RS3 samples 
The digestibility of RS3s was determined following a previously reported method (Chen, Liang, 
Li, Chen & Xie, 2016). Based on the rate of hydrolysis, starch was defined as rapidly-digestible 
starch (RDS, digested within 20 min), slowly-digestible starch (SDS, digested between 20 min and 
120 min), and RS (undigested within 120 min).  
 
2.4.2. X-ray diffraction (XRD) 
XRD analysis was performed with an Xpert PRO diffractometer (PANalytical, Netherlands), 
according to the earlier method (Chen, Liang, Li, Chen & Xie, 2016). The relative crystallinity (RC) 
of each sample was calculated using a previous method of Hermans (Hermans & Weidinger, 1948). 
The ratio of the upper area (crystalline portion) to the total diffraction area (based on a linear baseline) 
was taken as the RC with the software MDI Jade 6.0. 
 
2.4.3. Gel permeation chromatography (GPC) coupled with multi-angle light scattering (MALS) 
A GPC system coupled with a MALS detector (632.8 nm, DAWN HELEOS, Wyatt Technology, 
Santa Barbara, CA, USA) and a refractive index (RI) detector (Optilab rex, Wyatt Technology) was 
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used to determine the weight-average molecular weight (Mw), number-average molecular weight 
(Mn), and molecular weight distribution. The GPC system consisted of a pump (1515, Waters, 
Milford, MA, USA), an auto-injector with a 0.1mL loop (717, Waters), and three columns (Sytyragel 
HMW7 GPC column, Sytyragel HMW6E GPC column, Sytyragel HMW2 GPC column, respectively, 
7.8 × 300 mm, Waters). The data of light scattering was measured, collected and analyzed according 
to our earlier method (Situ, Chen, Wang & Li, 2014). 
 
2.5. Preparation of the RS2/RS3 film-coated MPs (RS@MPs) 
5-ASA-loaded MP cores (containing microcrystalline cellulose and medicinal starch in the ratio 
of 3:1 and the 5-ASA in the content of 16%, w/w) were obtained via extrusion–spheronization 
(Mini-250, Xinyite Co., Ltd., Shenzhen, China) (Pu, Chen, Li, Xie, Yu & Li, 2011). Different content 
of native starch particles (HACS, 3%, 5%, and 10%, w/w) were added to 5% (w/w) polymer pastes 
(RS3, PVP and HPMC), and 5% (w/w) triethyl citrate was added into the suspensions, which were 
then stirred for 8 h by a magnetic stirrer to form stable starch-based aqueous coating suspensions. 
The 5-ASA-loaded MP cores were coated using a bottom-spray fluid-bed coater (Mini-XYT; 
Xinyite Technology Co., Shenzhen, China) to achieve the coated-film thickness of 16–50% (w/w, the 
dry weight gain of MPs) (Pu, Chen, Li, Xie, Yu & Li, 2011). The process parameters were as follows: 
motor speed at 1500–2000 rpm; inlet temperature at 55–60 °C; temperature of bioactive 
component-loaded MPs at 28–31 °C; spray rate of coating dispersion at 1–1.5 mL/min; atomization 
pressure at 0.15–0.2 MPa; and fluidization pressure at 0.04 MPa.  
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2.6. In vitro release testing  
The release of 5-ASA from the different film-coated MPs (PVP, HPMC, and RS2/RS3) was 
carried out using a dissolution rate test apparatus (RCZ-8B, Tianda Tianfa Co., Ltd., Tianjin, China) 
(100 rpm, 37 °C) according to the USP23 dissolution method (Labastie, Solange, Brandão & Cumps, 
1998). The MPs were incubated in SGF for the first 2 h, then in SIF for another 6 h. 5 mL of each 
sample was taken at appropriate time intervals and analyzed for 5-ASA content using a UV 
spectrophotometer (Unico, UV-3802, Shanghai, China). The calibration curves of 5-ASA for SGF 
(R2 = 0.9999) and SIF (R2 = 0.9990) were used for the determination of 5-ASA release percentage. 
 
2.7. In vivo release testing in mice and the related morphological observation 
The FITC-loaded RS@MPs (loaded content: 2%, w/w) were prepared by the method described 
in Section 2.5 with minor modifications to fit the GIT transition time in mice. According to our 
preliminary tests, the gastric residence time in mice was 2 min, and the small intestinal residence 
time in mice was 42 min. After 44 min, RS@MPs entered the colon physiological environment. 
Three eight-week-old male nude mice (NO.11400700045743, Beijing Vital River Laboratory 
Animal Technology Co., Ltd., Beijing, China), each weighing 18–22 g, were fasted for 24 h before 
the test. FITC-loaded RS@MPs (80 mg/kg of rat) in 0.1 mol/L phosphate buffered saline (PBS) 
buffer (pH 7.4) were injected into one mouse by intragastric administration via polyethylene tubing 
(experiment group). The other two mice were injected with an equivalent amount of PBS solution 
(blank control group) and uncoated FITC-loaded MPs in PBS buffer (reference group), respectively. 
Then, the three treated mice were anesthetized with isoflurane immediately and subject to 
spatiotemporal detection of FITC transition along the GIT using an IVIS (IVIS 200, Xenogen Co., 
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Ltd., Alameda, Canada). In vivo fluorescent images (the excitation spectrum: 445-490nm; the 
emission spectrum: 515-575nm) were captured at the predetermined time points (10 min, 20 min, 50 
min, 80 min, 120 min, and 180 min) after the intragastric administration of FITC-loaded MPs to the 
experimental mice.  
36 thirteen-week-old Institute of Cancer Research (ICR) mice (NO.11400700045743, Beijing 
Vital River Laboratory Animal Technology Co., Ltd., Beijing, China), half male and half female, 
each weighing 18–22 g, were fasted for 24 h before the test. The FITC-loaded RS@MPs (80 mg/kg 
of rat, the experiment group) and uncoated FITC-loaded MPs (80 mg/kg of rat, the reference group) 
were orally administered to the stomach via polyethylene tubing. At certain times after their oral 
administration (10 min, 20 min, 40 min, 80 min, 4 h, and 24 h), the rats were sacrificed by cervical 
dislocation, and the tissues of the stomach, small intestine, and colon were obtained. Then, the OCT 
compound (McCormick Cryo-STAT)-embedded tissue sections of the stomach, small intestine, and 
colon of the rats were sliced into 6 µm depth by a cryostat microtome (Shandon cryotoZFE, Thermo 
Fisher Scientific Co., Ltd., Waltham, USA) at −20 °C. Afterwards, the section slides were dyed with 
DAPI for histospectroscopy using a two-photon confocal laser scanning microscope (Zeiss 710 NLO, 
Zeiss, Germany). The process parameters were as follows: wavelength filter: 491–545 nm; objective 
lens: Plan-Apochromat 20x/0.8 M27; pinhole detector: 150 µm; pixel dwell: 1.58 µs; repeated 
scanning time: line 2. 
 
2.8. Statistical analysis 
The mean values and differences were analyzed using Duncan’s multiple-range test. Analysis of 
variance (ANOVA), followed by the least significant difference test (LSD-test), was performed using 
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SPSS (Version 22.0) software. The significance level was set at p < 0.05. 
 
3. Results and discussion 
3.1. Characteristics and in vitro digestion analysis of native starches 
Being administrated orally, DDSs face several physiological challenges such as the acidic pH in 
the stomach and the digestive enzymes in the intestine (Hamman, Enslin & Kotzé, 2005), which 
could require the resistance of drug carrier materials to protect the carried pharmacologically active 
agents. As seen from Table 1, regardless of amylose content, all native starches showed high 
enzyme-resistance (Undigested starches: 85.6–89.6%), suggesting they are good sources of RS2. 
Still, there was a significant difference in RS content among native starches with different amylose 
contents. Specifically, native starches with a high amylose content (≥ 50%) were less susceptible to 
acid or enzymes than others with high amounts of amylopectin (NCS and WCS). This difference can 
be explained by the higher amount of B-type crystalline structure with an increase in amylose 
content (Cheetham & Tao, 1998), which was intrinsically resistant to acid (Gérard, Colonna, Buléon 
& Planchot, 2002; Vermeylen, Goderis, Reynaers & Delcour, 2004) or enzymatic degradation (Jane, 
Wong & McPherson, 1997). Depending on the packing of the amylopectin side chains into double 
helices, the starch crystalline structure can be normally described as either A, B, or C (Luengwilai & 
Beckles, 2009). Compared with A-type crystalline structure in NCS and WCS (Cheetham & Tao, 
1998), B-type crystallites have been proposed to be accompanied by a higher amount of long chains 
and more branch points in non-crystalline regions, leading to high-density amorphous regions and 
stable crystallites, which resist enzymatic hydrolysis (Jane, Wong & McPherson, 1997). Besides, the 
B type has been assumed to contain larger blocklets supposedly arrange in a peripheral ring of starch 
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granules, which acts as a barrier to hydrolytic enzymes (Oates, 1997). However, as H3O
+ ions can 
diffuse easily within the granule, this organization could not account for the behavior of acid 
hydrolysis. The acid resistance of B-type crystallites may result from their intrinsic stability, 
three-dimensional size, their size along the c-axis, and/or a greater perfection (Planchot, Colonna & 
Buleon, 1997). Furthermore, especially after 6 h of incubation in SIF, their resistance decreased with 
a higher amylose content with the same crystalline type among native starches. Since the amount of 
double-helical order in native starches should be strongly correlated to the amylopectin content, the 
granule’s crystallinity decreased with amylose content (Gernat, Radosta, Anger & Damaschun, 1993), 
thus, higher susceptibility to enzymatic degradation. 
 
 
Table 1 Amylose content and in vitro digestion of native starches 
Native 
starches 
Amylose 
(%) 
Digested starch in SGF (%) Digested 
starch in 
SIF (%) 
Undigested 
starch (%) 
G80 80±2a 0.25±0.02b 11.5±0.2c 88.3±0.2c 
HACS 72±2b 0.23±0.01b 11.3±0.2cd 88.5±0.3cd 
Hylon V 51±2c 0.23±0.02bc 11.1±0.1d 88.7±0.1d 
G50 50±2c 0.24±0.01b 10.1±0.1e 89.6±0.1e 
NCS 28±1d 0.32±0.01a 14.1±0.2a 85.6±0.2a 
WCS 1±0.3e 0.26±0.01b 12.5±0.1b 87.3±0.1b 
Values are means of three determinations (±standard deviation); values followed by the different letters within a column 
differ significantly (p < 0.05). 
 
 
The degree of hydrolysis can be influenced by both the granule parameters (size and surface 
features) and internal structure of starch. From SEM micrographs (Fig. 1), all native cornstarch 
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granules were irregular in shape and displayed a similar range of sizes (3-26 µm). In addition, the 
surfaces of high amylose starches (G80, HACS, Hylon V, and G50) were comparatively smooth 
without scratches, whereas small pores and pits were found randomly distributed on the surface of 
NCS and WCS granules. These surface pores were suggested to be openings to channels that 
penetrate in a roughly radial direction through the granule (Fannon, Shull & BeMiller, 1993).  
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Fig. 1. SEM images of native and hydrolyzed starch residues. 
 
3 µm 
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WCS WCS-SIF WCS-SGF 
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3 µm 3 µm 3 µm 
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The susceptibility of starch granules can be classified by the manner and degree by which the 
granules are eroded and corroded. As seen from SEM images, the surface erosion of all six 
hydrolyzed starch granules was marginal, which was in accordance with the high resistance of native 
starches (Table 1). Yet, the degree of hydrolysis varied among different starch granule features and 
was intensified by the subsequent enzymatic degradation after acidic hydrolysis. After 2 h in SGF 
and 6 h in SIF of incubation, no apparent hydrolysis of G80 and HACS was seen, with the surfaces 
becoming slightly rougher with some pitting (G80-SIF and HACS-SIF in Fig. 1) but still resembling 
those of the native starch granules. In contrast, more apparent hydrolysis of G50 and Hylon V was 
observed as more rugged granule surfaces with increased pinholes and furrows after incubation in 
SGF and SIF. This difference existed despite that G50 and Hylon V had a higher resistance than G80 
and HACS. However, compared with high amylose starches (G80, HACS, Hylon V, and G50), the 
erosion profiles of NCS and WCS were much obvious from the increased surface roughness and the 
formation of hole depressions in many granules (NCS-SIF, WCS-SGF, and WCS-SIF in Fig. 1). For 
high-amylose starches, the intensity of digestion could be tempered due to the smooth surface 
without pores as the amylose molecules fill the gaps/spaces (Bertoft & Manelius, 1992), which was 
another reason for lower susceptibility to digestion. Thus, high-amylose starches (G80, HACS, 
Hylon V, and G50) with high acid/enzyme-resistance can be good choices as suspension particles in 
the film-coating process. Also, with the consideration of comparatively low price and low 
susceptibility to corrosion, HACS was finally chosen as suspension particles to increase the RS 
content of RS@MPs. 
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3.2. Preparation and characteristics of RS3 samples. 
Owing to the necessary resistibility of starch-based films to realize the colon-specific delivery by 
the coated MPs, RS3s with different characteristics have been prepared by physical modification. 
Because of the significant roles of pullulanase activity and the starch concentration of paste in the 
formation of RS3s (Situ, Chen, Wang & Li, 2014; Zhang, Chen, Zhao & Li, 2013), these two 
parameters were exclusively investigated to compare the preparation and characteristics of RS3 
samples. Fig. 2 A-B show the RDS, SDS, and RS results of modified starch samples. Compared with 
native Hylon V, an apparent increase in RS content and a decrease in RDS content were observed for 
all the modified samples. These results demonstrated that the digestion resistibility of starch could be 
improved by the HTP and debranching treatments and the following retrogradation and drying 
processes. Through the process of recrystallization, the gelatinized starch (amylose and debranched 
short starch molecules) can be transformed from an amorphous state to a more ordered or crystalline 
state, which has a high enzymatic resistance (Sajilata, Singhal & Kulkarni, 2006). However, no 
apparent increase in SDS content was seen for these samples, and in most cases, there was a lower 
SDS content than that of Hylon V (SDS: 9.8±0.6%). This trend of SDS variation was not surprising 
since amylopectin had a major impact on the inherent slow digestion property of starches (Zhang, Ao 
& Hamaker, 2006). After treatment, the branched structure of amylopectin was destroyed, so less 
SDS chains were recrystallized and formed.  
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Fig. 2. Effect of enzymatic activity (A) and starch concentration of paste (B) on the RDS, SDS, and RS contents of 
the debranched HTP-treated Hylon V; and XRD of different RS3 samples (C). The standard deviations of (A) and 
(B) were within 1.9% and 1.4%, respectively. 
 
 
Fig. 2A shows the effect of enzymatic activity on the formation of RDS, SDS, and RS when the 
starch concentration was fixed at 5% (w/w). As seen in Fig. 2A, debranching could further increase 
the RS content compared with the samples with only HTP treatment (0 ASPU/g). Regarding this, 
debranching would give starch chains a greater chance to align and aggregate to form ordered 
structures, thereby leading to a higher RS content. Increasing the pullulanase activity raised the RS 
content until a maximum of 76.6% (±1.1%) RS was reached at 100 ASPU/g. When the pullulanase 
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content was increased to 200 ASPU/g, the RS content was reduced to 59.5% (±1.9%). The HTP and 
debranching treatments with a suitable amount of pullulanase could lead to the gelatinization and 
destruction of starch granules, resulting in an irreversible swelling and degradation of starch 
molecules. Then, during retrogradation, some of the degraded starch chains of suitable molecular 
weight could reassociate to form tightly packed structures stabilized by hydrogen bonding, which 
would render α-1,4 glucosidic linkages inaccessible to enzymes to hydrolyze, leading to a higher 
RS3 content. However, with a further increase in pullulanase activity, the starch molecules could be 
degraded further, and these molecules could not preferably form tightly-packed ordered aggregations; 
thus, a decrease in RS content resulted (Pongjanta, Utaipattanaceep, Naivikul & Piyachomkwan, 
2009).  
On the other hand, for the samples subject to the HTP and branching treatments at 100 ASPU/g, 
a paste starch concentration of 5% could lead to the maximum RS content. The RS content just 
declined slightly with the increased starch concentration (Fig. 2B), which suggested that a high 
starch concentration might hinder the formation of RS. This result can be explained by the diffusion 
of starch molecules during retrogradation. When the starch concentration was low, despite the less 
chance of starch molecules to reassociate, there could be more free space for starch chains to 
entangle and orientate for more perfect crystalline structures, leading to high enzymatic resistibility 
(Ottenhof & Farhat, 2004). In contrast, a higher starch concentration resulted in an increased 
viscosity, which could hinder the movement and orientation of starch chains. In this way, imperfect 
crystallites tended to form, resulting in a lower RS content. Since a starch concentration of 5% was 
favorable for RS3 formation, this concentration of RS3 paste was selected for the further preparation 
of RS2/RS3 film-coating suspension. 
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The enzymatic resistibility of RS3 was related to the molecular structure (linear or branching, 
and molecular weight) of starch during retrogradation and the ordered structure of retrograded RS3. 
Here, RS3 samples with different degrees of pullulanase activity were characterized for molecular 
weight and crystalline structure. Fig. 2C shows the XRD patterns of native and RS3 samples. Their 
calculated RC values are shown in Table 2. It can be seen that all the samples (Hylon V and RS3s) 
displayed a B+V type hybrid polymorph, with main diffraction peaks of a typical B-type crystalline 
structure at around 5.6°, 17°, 22.0°, 23.4°, and 26.0° (Luengwilai & Beckles, 2009), and one peak at 
19.8°, which was related to the V-type crystalline structure (Buléon, Colonna, Planchot & Ball, 
1998). The V-type crystalline was caused by amylose–lipid complex, which has been proposed to 
hinder the enzymatic hydrolysis by covering the starch granule surface, leading to an increased 
content of RS (Crowe, Seligman & Copeland, 2000; Cui & Oates, 1999; Tufvesson, Skrabanja, 
Björck, Elmståhl & Eliasson, 2001). Compared with the XRD pattern of native Hylon V starch, most 
of the peaks (B+V) of RS3 samples became clearer. Their intensity was slightly enhanced after only 
HTP treatment and increased gradually as the degree of debranching increased. However, when the 
pullulanase activity reached 200 ASPU/g, the intensity of XRD pattern was slightly decreased. These 
results were further revealed and supported by RC data. The RC of native Hylon V was 10.30%, and 
increased after the HTP treatment and further increased by debranching. The maximum RC was 
78.34% at 100 ASPU/g pullulanase activity. The result of the crystalline structure is consistent with 
the analysis of RS content (Fig. 2A).  
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Table 2. GPC-MALS results and crystallinity of debranched HTP-treated RS3 samples 
Pullulanase 
activity (ASPU/g) 
Mw (g/mol) Mw/Mn < 105B (%) 105–106 (%) 106–107 (%) >107 (%) RC 
(%) 
Hylon V 6.385×106 (1% A) 4.085 (2%) 0 31.62 50.16 18.22 10.30 
0 1.567×106 (1%) 2.991 (2%) 0 71.79 25.38 2.83 36.55 
50 3.516×105 (0.7%) 2.030 (1%) 0 95.84 4.16 0 71.06 
75 2.175×105 (0.7%) 1.987 (2%) 36.40 61.26 2.34 0 72.20 
100 2.067×105 (1%) 1.534 (2%) 21.81 76.74 1.45 0 78.34 
200 1.329×105 (1%) 1.369 (2%) 33.22 66.78 0 0 76.59 
A Precision of global fit. B means the molecular distribution of Mw with units (g/mol). 
 
 
Table 2 shows the GPC-MALS results of native Hylon V and modified starches. After the HTP 
treatment, the Mw of Hylon V was reduced sharply from 6.385×10
6 to 1.567×106 g/mol. The Mw of 
HTP-treated samples was further reduced distinctly with debranching, and this value was even lower 
with more intensive debranching. This result confirmed the degradation of starch molecules by HTP 
and debranching. With the branching process, the Mw/Mn value, which reflects the polydispersity of 
molecular weight, was also seen to be decreased, suggesting the increased uniformity of molecular 
weight of modified starches. Moreover, Table 2 shows that with increased debranching, the high 
molecular fractions (Mw >10
7 g/mol and 106 < Mw < 10
7 g/mol) gradually decreased to nil, while the 
low molecular fraction (Mw <10
5 g/mol) was substantially increased. Combined with the RS content 
and Mw parameters, it can be concluded that the starch molecules with Mw = 2.067×10
5 g/mol 
favored the alignment and arrangement of double helices to form ordered structures during 
retrogradation. Moreover, the large amounts of ordered crystalline structure (B+V type) could be the 
main reason for the enhanced starch resistance to enzymatic digestion. 
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3.3. RS2 as the suspended particles and RS3 paste as the binder for RS2/RS3 film-coated MPs 
(RS@MPs) 
According to the results in Section 3.2, 5% concentration of RS3 paste with Mw = 2.067×10
5 
g/mol was selected for the preparation of RS2/RS3 aqueous film-coating suspension. To study the 
potential of RS3 starch paste as a binder to prepare a compact and firm film, the release behavior of 
5-ASA-loaded RS@MPs was compared with those MPs coated by films using two typical binder 
polymers (PVP and HPMC) incorporated with RS2 granules. 
As seen in the Fig. 3A, the release behavior of RS@MPs was similar to those film-coated MPs 
with PVP or HPMC, suggesting that the binding capability of RS3 paste was comparable to that of 
typical polymer binders. However, all of three film-coated MPs (with RS2/RS3, RS2/PVP, or 
RS2/HPMC) showed a rapid release, especially in the case of RS3 paste as the binder. The release 
percentage of 5-ASA from RS@MPs was up to 68.6 % (±2.6%) at the end of 2 h in SGF, indicating 
the inability for colon-targeted delivery. To inhibit the rapid release of bioactive component, the film 
coating process was improved by a double-coating method, i.e., 50% of suspension used for film 
firstly, and then the left 50% of suspension used for coating on top of the prior formed film. 
Compared with the single-coating method, the double-coating method of RS@MPs significantly 
reduced the release rate, with reduced release percentage in SGF (40.1±0.6%) and reduced total 
release percentage (54.5±1.0%) after another 6 h in SIF, showing a good potential of colon-specific 
delivery. Still, there was a burst release from 5-ASA loaded RS@MPs with the release percentage up 
to 35.0 % (±2%) at the end of 1 h in SGF. This fast release could be ascribed to the bioactive 
component molecules that were mostly loaded at or near the surface of the MPs (Woo, Jiang, Jo & 
DeLuca, 2001). In the following experiments, the double-coating method was used for a better 
AC
CE
PT
ED
 M
AN
US
CR
IPT
28 
release behavior of RS@MPs.  
 
 
 
Fig. 3. Effects of polymers (PVP, HPMC, and RS3) (A), RS2 granule content (B) of RS2/RS3 coating film, and 
film coating thickness (C) on the release behavior. The standard deviations of (A), (B) and (C) were within 2.6%, 
3.9% and 2.5%, respectively. 
 
 
Concentration of polymers: 5% (w/w); concentration of HACS: 5% 
(w/w); 5-ASA load: 16% (w/w); thickness of film coating: 50% (w/w) 
Concentration of Hylon V paste: 5% (w/w); concentration of HACS: 
10% (w/w); 5-ASA load: 16% (w/w) 
Concentration of Hylon V paste: 5% (w/w); 5-ASA load: 16% (w/w); 
thickness of film coating: 50% (w/w) 
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3.4. In vitro 5-ASA release from RS@MPs 
To optimize the colon-specific release property of 5-ASA loaded RS@MP delivery system 
further, the effects of RS2 (HACS) granule content and film coating thickness on the 5-ASA release 
behavior from the RS@MPs in the simulated human GIT were investigated, with the results 
presented in Fig. 3. As another main film component, the content of RS2 granules may play a vital 
role in the film quality. Therefore, the in vitro release of 5-ASA from RS@MPs containing different 
content (3–10%, w/w) of HACS granules were evaluated, and the results are shown in Fig. 3B. It can 
be seen that the 5-ASA release in SGF and SIF decreased with the increased HACS granules content. 
This can be explained by the high acidic and enzymatic resistance of HACS granules (Table 1) and 
the enhanced mechanical strength of RS2/RS3 film by the addition of HACS granules (Hari & Nair, 
2016). With the increased content of HACS granules, the RS2/RS3 film was much firmer and 
suffered less erosion in SGF and SIF. Thus, the diffusion of 5-ASA was hindered and less released 
from RS@MPs with a higher RS2 content. When the content of HACS granules was 10%, the 
release percentage from RS@MPs was 40.7% (±2.3%) for 8 h in the upper GIT, indicating that these 
RS@MPs could target the bioactive components to the colon. Therefore, a HACS granule content of 
10% should be suitable for preparing RS@MPs with good colon-targeted controlled-release 
performance.  
The coating film thickness could also be an important parameter to control the release behavior 
of RS@MPs. Fig. 3C shows the percentages of release from RS@MPs with different thicknesses of 
film coating (13.8%–50%) when the content of HACS granules was fixed at 10%. As expected, the 
release percentage decreased with increasing the film-coating thickness. This was because the 
increased film-coating thickness could significantly increase the length of the diffusion pathways for 
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the bioactive component. With the consideration of colon-targeted release performance, a 
film-coating thickness of 50% was preferable. The results discussed above (Fig. 3) have shown that 
the colon-targeted release behavior of RS@MPs could be well adjusted by the formulation of 
suspensions and process parameters. 
 
3.5. In vivo release fluorescein from RS@MPs 
We also assessed the in vivo behavior of RS@MPs in terms of the residence time of formulation 
in different parts of the GIT. By IVIS, the FITC release behavior from RS@MPs in mice was studied. 
Fig. 4 shows the in vivo images of FITC distribution at different times in nude rats after 
administration of PBS solution (left), FITC-loaded uncoated MPs (middle), and RS@MPs (right). It 
can be seen that there was no fluorescent spot found on the nude mice injected by PBS solution for 
the whole experiment period (from 10 to 180 min), indicating no autofluorescence phenomenon 
occurred in nude mice under IVIS. As for uncoated MPs, large and bright fluorescent spot was found 
on the stomach of mice at 10 min after intragastric administration (Fig. 4A), showing a rapid release 
of FITC from uncoated MPs. From 20 to 50 min after intragastric administration, the fluorescence 
spot enlarged and moved from the stomach to the small intestine and colon part of the nude mice 
(Fig. 4B-C). This observation indicated a continuous release of FITC from uncoated MPs along the 
whole GIT. The released FITC could be absorbed into the gastrointestinal tissue and then into the 
blood circulation system gradually. Thus, from 80 to 180 min after intragastric administration, it can 
be seen that the fluorescence was spreading with the blood circulation throughout the body (Fig. 
4D-F), and the intensity was decreasing due to the metabolism of FITC.  
When RS@MPs were used for intragastric administration, the release rate of FITC was found to 
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be much slower than that of uncoated MPs. At 50 min after intragastric administration, the 
fluorescent spot remained small, suggesting a quite limited release of FITC from RS@MPs in the 
upper GIT of mice (Fig. 4C). From 80 to 120 min after intragastric administration, the fluorescent 
spot was at the colon part of mice and enlarged (Fig. 4D-E). The intensity of fluorescence increased 
but still not as bright as in the reference group, showing the comparatively slow release rate of FITC 
from RS@MPs. At 180 min after intragastric administration, the fluorescent spot had spread across 
the whole body.  
 
 
 
Fig. 4. FITC distribution in the gastrointestinal epithelial tissues for different times (from left to right: blank control, 
reference and experiment group): (A) 10 min; (B) 20 min; (C) 50 min; (D) 80 min; (E) 120 min; and (F) 180 min.  
A B C 
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To further understand the release behavior of RS@MPs, the images showing the FITC 
distribution in the GIT epithelial tissues of mice after intragastric administration were studied by 
tissue histospectroscopy. Fig. 5 shows FITC distribution in the GIT epithelial tissues of mice after 
administration of the uncoated MPs for different times. At 10 min after administration, large and 
strong fluorescence were found on the stomach and the small intestine epithelial tissues of mice (Fig. 
5A-B), indicating the rapid release of FITC from uncoated MPs without the protection of a film. The 
fluorescence on the stomach and small intestine remained strong up to 40 min after administration 
(Fig. 5D-E and G-H) because of the continuous release of FITC in the upper GIT and absorption of 
FITC in epithelial tissues. Along this time, the intensity of fluorescence in the colon epithelial tissues 
still existed but was weak (Fig. 5C, F, and G), showing no release of FITC in the colon. Here, the 
weak fluorescence in the colon might be caused by some operation error. At 80 min after 
administration, the intensity of fluorescence in the colon epithelial tissues enhanced, suggesting the 
MPs was transported to the colon (Fig. 5L). From 80 min to 24 h, the fluorescence intensity at the 
colon gradually increased, while the fluorescence intensity of the stomach and small intestine of the 
mice gradually weakened (Fig. 5M-R). Yet, due to the massive release of FITC in the upper GIT, 
there was still high fluorescence in the stomach and small intestine tissues. 
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Fig. 5. FITC distribution in the gastrointestinal epithelial tissues of rats after administration of the reference group 
for different times: (A) stomach, 10 min; (B) small intestine, 10 min; (C) colon, 10 min; (D) stomach, 20 min; (E) 
small intestine, 20 min; (F) colon, 20 min; (G) stomach, 40 min; (H) small intestine, 40 min; (I) colon, 40 min; (J) 
stomach, 80 min; (K) small intestine, 80 min; (L) colon, 80 min; (M) stomach, 4 h; (N) small intestine, 4 h; (O) 
colon, 4 h; (P) stomach, 24 h; (Q) small intestine, 24 h; and (R) colon, 24 h. 
 
 
Fig. 6 shows the FITC distribution in the GIT epithelial tissues of mice after administration of 
RS@MPs for different times. Compared with the uncoated MPs (Fig. 5), at 10, 20 and 40 min after 
administration, the intensity of fluorescence in the stomach and small intestine was much weaker 
(Fig. 6A-B, D-E, and G-H), especially at 10 min after administration, suggesting the RS2/RS3 film 
had high resistibility and inhibited the FITC release in the upper GIT. Moreover, there was almost no 
fluorescence in the colon tissues (Fig. 6A-B, D-E, and G-H). Similar to the uncoated MPs, from 80 
M N 
P Q R 
O 
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min to 24 h after administration, the colon epithelial tissues showed fluorescence and this 
fluorescence became more intense (Fig. 6L, O, and R). Moreover, compared with the uncoated MPs 
(Fig. 5L and O), the intensity of fluorescence was comparatively stronger (Fig. 6L and O). This 
observation clearly indicates the enhanced release of FITC from RS@MPs, which may be due to the 
fermentation of RSs by anaerobic microflora in the colon (Rubinstein, 1990). These results clearly 
demonstrate that RS@MP had a colon-targeted property and well-controlled release behavior. 
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Fig. 6. FITC distribution in the gastrointestinal epithelial tissues of the experiment group for different times: (A) 
stomach, 10 min; (B) small intestine, 10 min; (C) colon, 10 min; (D) stomach, 20 min; (E) small intestine, 20 min; 
(F) colon, 20 min; (G) stomach, 40 min; (H) small intestine, 40 min; (I) colon, 40 min; (J) stomach, 80 min; (K) 
small intestine, 80 min; (L) colon, 80 min; (M) stomach, 4 h; (N) small intestine, 4 h; (O) colon, 4 h; (P) stomach, 
24 h; (Q) small intestine, 24 h; and (R) colon, 24 h. 
 
 
P Q R 
O N M 
J K L 
AC
CE
PT
ED
 M
AN
US
CR
IPT
38 
4. Conclusion 
The developed method based on RS2/RS3 film is safe and simple, aiming at 
starch-only-film-coated colon-specific DDSs by physical modification. RS2 came from 
high-amylose starch particles with a smooth surface and B-type crystalline structure. RS3 with high 
crystallinity was generated by the recrystallization of starch molecules with suitable Mw. Thus, the 
resistibility of the coating film was improved by RS2 and recrystallized RS3 to hinder the active 
compound release. Moreover, for the formation of RS2/RS3 film, RS3 paste acted as a binder. 
Importantly, for RS@MPs, desired colon-targeted release performance can be easily obtained by 
adjusting the content of RS2 and RS3 as well as the film-coating thickness of the coated RSA film. 
This study shows the ability of the newly developed starch-based coating to effectively delivery 
active compounds (e.g., 5-ASA) into the colon. 
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